Healthcare (Substance Abuse)

in committee · New Jersey · General Assembly Jan 13, 2026

A 1593: Establishes certain protocols for prescribing and dispensing benzodiazepine.

This bill establishes new rules for prescribing and dispensing benzodiazepines (like Xanax and Valium) and similar sleep medications (like Ambien). It requires healthcare providers to give patients a detailed pamphlet about risks, obtain signed consent, and use bold labels warning of addiction risks. Prescriptions for these drugs cannot exceed four weeks without medical justification, and providers must follow safe tapering protocols to help patients reduce use gradually. The rules apply to most patients but exclude those receiving care in long-term facilities like nursing homes.

Topics ✓ HealthcareSupports HealthcareRequires patient risk education, consent, and prescription limits to prevent addiction, directly protecting patient safety in healthcare services.90% confidence

Sub-Topics Substance Abuse

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 538: "Pharmaceutical Representative Licensing Act."

This bill (A 538, "Pharmaceutical Representative Licensing Act") requires all individuals marketing pharmaceuticals to healthcare practitioners in New Jersey to obtain a state license. It directly affects pharmaceutical sales representatives, who must meet education, ethics, and background requirements, complete biennial continuing education (including opioid safety training), and report all interactions with doctors - including promoted drugs, samples given, and gifts provided. The State Board of Medical Examiners will oversee licensing, enforce standards (like banning deceptive marketing or false medical credentials), and may suspend licenses for violations. The bill aims to increase transparency and professionalism in pharmaceutical sales interactions.

Topics ✓ HealthcareSupports HealthcareRegulates pharmaceutical marketing with ethics training, transparency, and opioid safety requirements to protect patient safety and promote ethical healthcare interactions.85% confidence

Sub-Topics Substance Abuse Tags Licensing

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 449: Requires institutions of higher education to have automatic external defibrillator on premises and maintain supply of naloxone hydrochloride.

This New Jersey bill (A 449) requires all colleges and universities to place automatic external defibrillators (AEDs) in unlocked locations within athletic facilities and student centers, accessible during normal operating hours. It also mandates that institutions maintain a supply of naloxone nasal spray near each AED for opioid overdose emergencies, with designated staff trained to use both devices. Institutions must ensure at least two staff members are CPR- and AED-trained during facility hours and regularly test/maintain equipment, while also designating a campus medical professional to oversee naloxone use. The bill provides liability protection for institutions and staff acting in good faith when implementing these requirements.

Topics ✓ EducationSupports EducationBill mandates safety equipment (AEDs/naloxone) at higher education institutions, enhancing student/staff safety and protecting the educational environment per support indicators.90% confidence ✓ HealthcareSupports HealthcareMandates AEDs and naloxone for cardiac/opioid emergencies in schools, improving emergency health access and public safety per healthcare topic definition.95% confidence

Sub-Topics Higher Education Substance Abuse

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 464: "HOPE Initiative Act"; requires establishment of public awareness campaign to educate citizens about dangers and causes of, and appropriate responses to, heroin and opioid addiction.

The "HOPE Initiative Act" (A464) requires New Jersey to establish a statewide public awareness campaign to combat the heroin and opioid epidemic. It mandates the Division of Mental Health and Addiction Services to develop a multicultural campaign ("HOPE Initiative") using all media channels to educate diverse audiences - including at-risk individuals, families, medical professionals, first responders, and employers - on addiction pathways, warning signs, treatment options, naloxone use, and prevention strategies. Key provisions include debunking myths about addiction, highlighting treatment benefits, promoting naloxone access, and addressing prescription opioid misuse. The campaign must use culturally appropriate messaging in multiple languages and leverage public-private partnerships for wider reach. This is a procedural bill focused on education, not regulatory changes.

Topics ✓ HealthcareSupports HealthcareMandates public awareness campaign on opioid addiction, promoting education about treatment and naloxone use to improve public health access and mental health support.95% confidence

Sub-Topics Mental Health Public Health Substance Abuse

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 1816: Requires hospitals to test for fentanyl and xylazine as part of urine drug screenings.

This bill requires New Jersey hospitals to include testing for fentanyl and xylazine in routine urine drug screenings when treating patients. It directly affects all general acute care hospitals licensed in New Jersey that conduct such screenings. Hospitals must report de-identified test results to the Department of Health if fentanyl, xylazine, or other drugs under a health alert are detected. The law aims to improve overdose response by ensuring these dangerous substances - linked to rising fatal overdoses - are identified during patient care.

Topics ✓ HealthcareSupports HealthcareMandates hospital testing for fentanyl/xylazine to improve overdose response, directly enhancing public health surveillance and patient safety in healthcare settings.90% confidence

Sub-Topics Substance Abuse

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 3364: Requires pharmacies to sell hypodermic syringes and needles to any customer over the age of 18 and post sign concerning consumer right to purchase clean syringes and needles.

This bill (A3364) requires New Jersey pharmacies to sell hypodermic syringes and needles to any customer aged 18 or older without a prescription for quantities of 10 or fewer. Pharmacies must also post a sign at the counter informing customers of this right, maintain syringe supplies behind the counter, and provide information about safe disposal and substance abuse treatment at the time of purchase. It directly affects pharmacies (mandating sales) and adults over 18 (who can purchase without a prescription for small quantities). The bill builds on existing law (P.L.2011, c.183) that previously allowed but did not require such sales, aiming to increase access to clean syringes to help prevent bloodborne diseases like HIV and hepatitis C.

Topics ✓ HealthcareSupports HealthcareEnables access to clean needles for safe use, reducing infection risks and supporting public health initiatives through harm reduction.90% confidence

Sub-Topics Substance Abuse

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 2308: Requires health insurance carriers to provide coverage for enrollment of student in recovery high school alternative education program.

This bill (A 2308) requires New Jersey health insurance carriers to cover enrollment in recovery high school alternative education programs for students with substance use disorders. It directly affects students in these programs and health insurers, mandating coverage when a certified professional (like a counselor or physician) determines it is clinically appropriate based on DSM criteria. The law specifies that this coverage must be provided under the same terms as other medical benefits, without extra copays, deductibles, or limits. It amends existing insurance laws to include this specific benefit for recovery high schools established under P.L.2015, c.254. The bill is currently pending before the Assembly Financial Institutions and Insurance Committee.

Topics ✓ EducationSupports EducationMandates health insurance coverage for recovery high school programs, expanding educational access for students with substance use disorders through required clinical coverage.95% confidence ✓ HealthcareSupports HealthcareMandates health insurers to cover substance use disorder recovery programs, expanding coverage for mental health services under same terms as other medical benefits.95% confidence

Sub-Topics K-12 Education Insurance Substance Abuse

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 3344: "Mental Health Access Act;" increases Medicaid reimbursement rates for certain evidence-based behavioral health services.

This bill increases Medicaid reimbursement rates for certain mental health services to at least the Medicare rate. It directly affects Medicaid-eligible patients (adults and children) and providers like licensed substance abuse treatment centers or mental health professionals offering evidence-based outpatient counseling. The key provision requires that services must be proven effective (listed in federal registries or approved by state officials) and limited to individual/group therapy in outpatient settings. This policy change aims to improve payment for specific behavioral health treatments under New Jersey's Medicaid program.

Topics ✓ HealthcareSupports HealthcareIncreases Medicaid reimbursement rates for mental health services to Medicare level, improving provider access and patient coverage for evidence-based care.95% confidence

Sub-Topics Medicaid Mental Health Substance Abuse

Track

in committee · New Jersey · General Assembly Jan 13, 2026

A 1804: Requires court to provide certain defendants with referral for mental health and substance abuse evaluation.

This New Jersey bill (A 1804) requires courts to refer certain defendants to mental health and substance abuse evaluations as part of pretrial release decisions. It directly affects eligible defendants who are being considered for release before trial but have potential mental health or substance use needs. The key provision mandates that courts must provide these referrals when determining release conditions, ensuring defendants have access to treatment as part of their pretrial supervision. The bill amends existing pretrial release laws (P.L.2014, c.31) to integrate these evaluations into the court's decision-making process. This policy change focuses on connecting defendants with treatment resources while maintaining court safety and appearance requirements.

Topics ✓ Criminal JusticeSupports Criminal JusticeMandates mental health/substance abuse evaluations for pretrial defendants, promoting rehabilitation and reducing recidivism through treatment access during pretrial supervision.95% confidence ✓ HealthcareSupports HealthcareMandates mental health referrals for defendants, improving access to treatment services as part of pretrial process95% confidence

Sub-Topics Courts Mental Health Substance Abuse

Track

in committee · New Jersey · General Assembly Jun 23, 2026

A 1821: Prohibits health insurance carriers from denying coverage of nonopioid prescription drugs in favor of opioid prescription drugs.

This bill prohibits health insurance carriers from denying coverage for nonopioid pain medications in favor of opioids or requiring patients to try opioids first. It requires insurers to treat FDA-approved nonopioid drugs equally to opioids in formularies, meaning coverage restrictions, prior authorization, and cost-sharing tiers must be no more restrictive for nonopioid drugs. The law applies to state health benefit plans, school employee health programs, and Medicaid for acute pain treatment. It takes effect January 1, 2026, directly affecting insurers and patients covered by these plans.

Topics ✓ HealthcareSupports HealthcareProhibits insurers from favoring opioids over nonopioid drugs, ensuring equal coverage and access to alternative pain treatments under state plans and Medicaid.95% confidence

Sub-Topics Insurance Medicaid Substance Abuse

Track